Health Catalyst, Inc. (NASDAQ:HCAT) Receives $4.32 Average Target Price from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has earned a consensus recommendation of “Hold” from the fourteen research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $4.3182.

A number of research analysts recently issued reports on the company. Cantor Fitzgerald reiterated a “neutral” rating and issued a $4.00 target price on shares of Health Catalyst in a report on Tuesday, October 7th. UBS Group reaffirmed an “outperform” rating on shares of Health Catalyst in a report on Tuesday, November 11th. Wells Fargo & Company decreased their price target on shares of Health Catalyst from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 11th. Stifel Nicolaus lowered their price target on shares of Health Catalyst from $4.50 to $3.75 and set a “hold” rating for the company in a report on Tuesday, November 11th. Finally, KeyCorp reduced their price objective on shares of Health Catalyst from $5.00 to $4.00 and set an “overweight” rating on the stock in a report on Wednesday, October 8th.

Insider Buying and Selling at Health Catalyst

In other news, Director Julie Larson-Green sold 47,997 shares of the firm’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $2.67, for a total transaction of $128,151.99. Following the sale, the director owned 73,573 shares of the company’s stock, valued at approximately $196,439.91. This trade represents a 39.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Benjamin Landry sold 27,425 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $2.64, for a total value of $72,402.00. Following the sale, the general counsel owned 100,000 shares of the company’s stock, valued at approximately $264,000. The trade was a 21.52% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

Hedge funds have recently added to or reduced their stakes in the stock. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Health Catalyst in the 3rd quarter valued at $39,000. Cresset Asset Management LLC acquired a new stake in Health Catalyst during the 2nd quarter worth $39,000. Divergent Planning LLC purchased a new stake in Health Catalyst in the second quarter valued at $45,000. FNY Investment Advisers LLC acquired a new position in Health Catalyst in the third quarter valued at $45,000. Finally, Focus Partners Wealth purchased a new position in shares of Health Catalyst during the first quarter worth about $46,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Trading Down 0.5%

Shares of HCAT stock opened at $2.15 on Friday. Health Catalyst has a fifty-two week low of $2.02 and a fifty-two week high of $5.90. The company has a 50 day moving average price of $2.46 and a 200 day moving average price of $2.90. The stock has a market capitalization of $152.07 million, a P/E ratio of -1.35 and a beta of 1.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.88 and a current ratio of 1.88.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Monday, November 10th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.01. The company had revenue of $76.32 million for the quarter, compared to analyst estimates of $75.05 million. Health Catalyst had a negative net margin of 34.05% and a negative return on equity of 6.67%. Equities research analysts predict that Health Catalyst will post -0.33 EPS for the current fiscal year.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.